Cite
HARVARD Citation
Feagan, B. et al. (n.d.). DOP027 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders. Journal of Crohn's and colitis. p. S050. [Online].